Abstract

Alphatec Holdings will publish its quarterly results on August 4, 2026 Post Market, with investors watching whether revenue growth and earnings leverage align with current forecasts following a quarter that featured resilient revenue, a high gross margin, and a breakeven adjusted EPS print.

Market Forecast

For the upcoming quarter, current projections indicate revenue of 211.27 million US dollars, up 18.16% year over year, adjusted EPS around 0.07, up 136.59% year over year, and EBIT of 15.96 million US dollars, up 174.57% year over year. Forecasts for gross margin and net margin were not disclosed in the collected projections. The main business is the U.S. Commercial franchise, which is expected to benefit from ongoing procedure momentum and operating leverage as case volumes and utilization stay supportive. The most promising area by revenue contribution remains the U.S. Commercial business at 192.11 million US dollars last quarter, up 13.55% year over year, reflecting durable demand.

Last Quarter Review

Alphatec reported quarterly revenue of 192.11 million US dollars, up 13.55% year over year, a gross profit margin of 71.04%, a GAAP net loss attributable to shareholders of 33.91 million US dollars translating to a net margin of -17.65%, and adjusted EPS of 0.00, up 100.00% year over year from a loss a year earlier. A key financial highlight was operating leverage: EBIT reached 5.58 million US dollars, up 112.61% year over year, indicating improved operating performance even as GAAP profitability remained negative. The main business driver was the U.S. Commercial franchise with revenue of 192.11 million US dollars, up 13.55% year over year, supported by steady case flow and utilization that helped sustain top-line momentum.

Current Quarter Outlook

Main business trajectory: U.S. Commercial execution

The core U.S. Commercial business sets the tone for the quarter. To meet the projected 211.27 million US dollars in revenue, the business needs to extend the 13.55% year-over-year pace seen last quarter toward the forecasted 18.16% year-over-year mark, which implies a moderate sequential acceleration. The EBIT forecast of 15.96 million US dollars (up from 5.58 million US dollars last quarter) suggests operating cost absorption and scale benefits are expected to improve, provided volumes remain on plan and mix stays favorable. Consistency of hospital procedure activity and efficient scheduling can help reduce variability and support unit throughput, which in turn supports the operating leverage reflected in the EBIT and EPS projections. Gross margin durability is a focal point. The last reported gross margin of 71.04% offers a cushion for earnings power, but the quarter’s profitability still hinges on the company sustaining premium mix, managing input costs, and maintaining utilization of instrument sets. If the company holds product mix near prior-quarter levels and executes effectively on logistics and field operations, the margin structure implied by the adjusted EPS forecast becomes more attainable. Visibility into pricing remains a consideration; steady pricing combined with mix of higher-value implants or enabling solutions typically helps protect the gross margin foundation. The GAAP net margin remained negative last quarter, which keeps attention on the income statement below gross profit, especially on operating expense discipline and interest cost. With EBIT expected to expand sharply year over year, the inflection narrative this quarter relies on turning operating improvements into earnings per share gains. The 0.07 adjusted EPS projection implies incremental flow-through relative to last quarter’s breakeven, which will likely be scrutinized against salesforce productivity, case conversion, and expense pacing over the quarter.

Most promising growth vector: Scaling case volumes within U.S. Commercial

Within the U.S. Commercial base, the largest growth potential lies in scaling case volumes and deepening account penetration, which last quarter supported revenue of 192.11 million US dollars, up 13.55% year over year. The 18.16% year-over-year revenue forecast implies further share capture or higher per-case revenue, and either path requires consistent execution in the field. Growing within existing hospital systems while expanding surgeon utilization can lift quarterly revenue without proportionate increases in selling expense, aiding EBIT leverage. Elevating per-case revenue through a richer mix can also contribute meaningfully. The more the company can position higher-value constructs and comprehensive solutions in spine procedures, the better protected the gross margin is from cost volatility. With EBIT expected to rise to 15.96 million US dollars this quarter, the operating model appears primed to benefit from scale if utilization and case mix progress as anticipated. The implication is that even modest mix improvement could add incremental basis points of margin and support the step-up from breakeven adjusted EPS to approximately 0.07. The full-year revenue outlook of about 882.00 million US dollars sets the context for the quarterly cadence. With 192.11 million US dollars delivered last quarter and 211.27 million US dollars projected for the current quarter, the implied first-half run-rate would approximate 403.38 million US dollars. That leaves roughly 478.62 million US dollars to achieve in the second half, or about 239.31 million US dollars per quarter on average, indicating an expected acceleration. Executing on that path likely depends on maintaining procedure momentum, improving set utilization, and continuing to deepen relationships in high-opportunity accounts.

What will matter most for the stock this quarter

Delivery versus the revenue and earnings trajectory will likely be the primary driver of the stock reaction. If revenue comes in around 211.27 million US dollars and EBIT tracks toward 15.96 million US dollars, investors may increasingly credit the operating leverage in the model, especially given last quarter’s gross margin level. Conversely, if volumes or mix fall short, the earnings bridge from breakeven adjusted EPS last quarter to about 0.07 could look ambitious, raising questions about the pace of operating leverage. Margin commentary will be crucial. Investors will listen for signals about sustainability of gross margin near the 71.04% watermark, including any discussion on product mix, pricing, and supply chain costs. Clarity on operating expense pacing relative to sales growth will inform how much of the incremental gross profit converts to EBIT, framing the trajectory of adjusted EPS for the second half. With EBIT forecast to more than double year over year, maintaining discipline in spending relative to the revenue base can be a differentiator for achieving and sustaining positive adjusted EPS prints. Capital structure and interest expense also matter for EPS translation. The company announced a debt refinancing that, based on the collected information, is expected to lower annual interest expense by over 6.00 million US dollars and extend maturities to 2031. While the full benefits may phase in over time, this initiative improves earnings visibility and cushions the path to sustained adjusted profitability. Any incremental color on timing and magnitude of interest expense savings could influence how investors model the progression from EBIT to adjusted EPS through the remainder of the year.

Analyst Opinions

Bullish views dominate the collected opinions during the period, with Buy or Overweight stances from multiple well-known institutions meaningfully outnumbering any cautious takes; among the notes gathered, the ratio of bullish to bearish is effectively 100% to 0%. Barclays reiterated a Buy with a 27.00 US dollars price target, citing a constructive outlook tied to top-line expansion and improving earnings power. Stifel maintained favorable views across several updates with targets in the mid-teens range; one note set a 16.00 US dollars target, supporting the notion that revenue growth and an improving operating profile can drive valuation support. Lake Street maintained a Buy with a 25.00 US dollars price target, highlighting upside potential as the company converts procedure momentum into operating leverage. Needham reaffirmed Buy with a 14.00 US dollars target following updated assumptions, reflecting confidence in the company’s ability to grow revenue while progressing toward consistent positive adjusted EPS. Additionally, Stephens initiated at Overweight with a 15.00 US dollars target, emphasizing the opportunity in scaling the commercial engine and harvesting operating efficiencies. UBS initiated at Buy with a 15.00 US dollars price target, underscoring the balance of revenue growth and profitability improvement as central to the equity case. Pulling these together, the common threads among bullish analysts are: expectations for mid-to-high teens revenue growth in the near term, belief in scaled operating leverage to lift EBIT and adjusted EPS, and a focus on milestone execution that aligns with the current-quarter forecasts. The breadth of Buy and Overweight ratings in recent months, combined with mid-teens to high-20s per-share price targets, indicates that the majority view anticipates progress toward sustained adjusted profitability and continued top-line momentum. Looking at the quarter specifically, bullish analysts will likely judge success by three markers. First, delivering revenue near the 211.27 million US dollars forecast with a gross margin profile consistent with the recent 71.04% reading would reinforce the margin narrative. Second, translating operating leverage into EBIT around 15.96 million US dollars would validate the cost absorption implied by recent investments. Third, stepping adjusted EPS up to approximately 0.07 would demonstrate that the path from breakeven last quarter to positive adjusted earnings is intact, with capital structure optimization providing an incremental tailwind to the EPS bridge. In aggregate, the prevailing institutional stance expects Alphatec Holdings to execute against these targets and maintain a credible trajectory toward the full-year revenue outlook of about 882.00 million US dollars, setting up the second half for continued progress in both growth and earnings leverage.